Pharmaceutical Engineering Company

Pharmaceutical plants
Design and construction. Turnkey GMP solutions.

Technical equipment

Validation Training
Pharmaceutical validation training courses

Validation Training
Long-term credits for joint development and reconstruction

FAVEA signed a tripartite agreement in Kazan

Cooperation in the production of biopharmaceuticals between Czech Republic and Russia has another completely new chapter of friendly relations. The Czech company FAVEA has signed an agreement with Tatarstan companies: "Tatneftekhiminvest-holding" and "Tatkhimpharmpreparaty", within the Czech-Tatarstan Business Forum held in June 2010.

tripartite agreement

The tripartite agreement signed by general director of "Tatneftekhiminvest-holding" Rafinat Yarullin, general director of "Tatkhimpharmpreparaty" Timur Khannanov and CEO of “FAVEA spol. s r.o.” Milan Krajíček in the presence of the Prime Minister of Tatarstan Ildar Khalikov and chairman of the Senate of the Czech Republic Přemysl Sobotka.

The agreement was one of the main stages in the establishment of new biopharmaceutical production in the Republic of Tatarstan under the program "Development of Biotechnology in the Republic of Tatarstan for 2010-2020". "The equipment of Czech company will be installed in the new production areas of the company "Tatkhimpharmpreparaty," which are around one thousand square meters," - said general director of “Tatneftekhiminvest-holding” Rafinat Yarullin. There will be produced innovative medicines: gels, ointments, including ointment, which is used to treat cancer. The volume of pharmaceutical production of company, which is currently around 1 billion rubles per year, will be tripled.

Company FAVEA has extensive experience on the international market and will function as an engineering company. Based on the agreement the Czech company will develop the project, provide technical equipment, clean-rooms, engineering systems for production, installation and commissioning, training and requalification of personnel.

In addition, FAVEA will participate in the development and introduction of new innovative biopharmaceuticals. For Tatar specialists the requalification courses will be held to cope with the new pharmaceutical production environment at their parent company.

Already this fall the documents governing the actions of all parties will be signed and the Czech-Russian working group will begin implementation of the agreement.